FindTrial
Sign In

Registration platform for immune-related adverse events of tumor immunotherapy

Registration platform for immune-related adverse events of tumor immunotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071948
Enrollment
Unknown
Registered
2023-05-30
Start date
2023-08-01
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer

Interventions

Group of malignant tumor:None

Sponsors

Renji Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. No age limit, male or female; 2. Diagnosed as malignant tumor by histology or cytology; 3. It is acceptable to accept or not accept surgery, chemotherapy, radiotherapy, local treatment or traditional Chinese medicine for the tumor in the past; 4. Patients with malignant tumors receiving immunotherapy; 5. Subjects voluntarily joined the study and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients who have not been diagnosed with malignant tumor or have not applied immunosuppressive agents.

Design outcomes

Primary

MeasureTime frame
irAE;—

Countries

China

Contacts

Public ContactXiuying Xiao

Renji Hospital, Shanghai Jiao Tong University School of Medicine

xiaoxiuying2002@163.com+86 13564579313

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026